294 related articles for article (PubMed ID: 23204187)
1. Practical outcome of adjuvant FOLFOX4 chemotherapy in elderly patients with stage III colon cancer: single-center study in Korea.
Kim JY; Kim YJ; Lee KW; Lee JS; Kim DW; Kang SB; Lee HS; Jang NY; Kim JS; Kim JH
Jpn J Clin Oncol; 2013 Feb; 43(2):132-8. PubMed ID: 23204187
[TBL] [Abstract][Full Text] [Related]
2. Weekly 24-h infusion of high-dose 5-fluorouracil (5-FU) with folinic acid (FA) in adjuvant therapy of colon cancer.
Wein A; Riedel C; Brückl W; Kastl S; Reingruber B; Hohenberger W; Hahn EG
Z Gastroenterol; 2001 Feb; 39(2):153-6. PubMed ID: 11253506
[TBL] [Abstract][Full Text] [Related]
3. Innovative chemotherapies for stage III colon cancer: a cost-effectiveness study.
Koperna T; Semmler D
Hepatogastroenterology; 2003; 50(54):1903-9. PubMed ID: 14696430
[TBL] [Abstract][Full Text] [Related]
4. Fluorouracil plus leucovorin as effective adjuvant chemotherapy in curatively resected stage III colon cancer: results of the trial adjCCA-01.
Porschen R; Bermann A; Löffler T; Haack G; Rettig K; Anger Y; Strohmeyer G;
J Clin Oncol; 2001 Mar; 19(6):1787-94. PubMed ID: 11251010
[TBL] [Abstract][Full Text] [Related]
5. Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA collaboration): final results from a prospective, pooled analysis of six randomised, phase 3 trials.
André T; Meyerhardt J; Iveson T; Sobrero A; Yoshino T; Souglakos I; Grothey A; Niedzwiecki D; Saunders M; Labianca R; Yamanaka T; Boukovinas I; Vernerey D; Meyers J; Harkin A; Torri V; Oki E; Georgoulias V; Taieb J; Shields A; Shi Q
Lancet Oncol; 2020 Dec; 21(12):1620-1629. PubMed ID: 33271092
[TBL] [Abstract][Full Text] [Related]
6. 5-Fluorouracil plus leucovorin is an effective adjuvant chemotherapy in curatively resected stage III colon cancer: long-term follow-up results of the adjCCA-01 trial.
Arkenau HT; Bermann A; Rettig K; Strohmeyer G; Porschen R;
Ann Oncol; 2003 Mar; 14(3):395-9. PubMed ID: 12598344
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and toxicity of adjuvant chemotherapy in elderly patients with colon carcinoma: a 10-year experience of the Geisinger Medical Center.
Fata F; Mirza A; Craig G; Nair S; Law A; Gallagher J; Ellison N; Bernath A
Cancer; 2002 Apr; 94(7):1931-8. PubMed ID: 11932894
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant therapy for stage III colon cancer after complete resection. Provincial Gastrointestinal Disease Site Group.
Figueredo A; Fine S; Maroun J; Walker-Dilks C; Wong S
Cancer Prev Control; 1997 Oct; 1(4):304-19. PubMed ID: 9765754
[TBL] [Abstract][Full Text] [Related]
9. Duration of Adjuvant Chemotherapy for Stage III Colon Cancer.
Grothey A; Sobrero AF; Shields AF; Yoshino T; Paul J; Taieb J; Souglakos J; Shi Q; Kerr R; Labianca R; Meyerhardt JA; Vernerey D; Yamanaka T; Boukovinas I; Meyers JP; Renfro LA; Niedzwiecki D; Watanabe T; Torri V; Saunders M; Sargent DJ; Andre T; Iveson T
N Engl J Med; 2018 Mar; 378(13):1177-1188. PubMed ID: 29590544
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the change of outcomes over a 10-year period in patients with stage III colon cancer: pooled analysis of 6501 patients treated with fluorouracil, leucovorin, and oxaliplatin in the ACCENT database.
Salem ME; Yin J; Goldberg RM; Pederson LD; Wolmark N; Alberts SR; Taieb J; Marshall JL; Lonardi S; Yoshino T; Kerr RS; Yothers G; Grothey A; Andre T; De Gramont A; Shi Q
Ann Oncol; 2020 Apr; 31(4):480-486. PubMed ID: 32085892
[TBL] [Abstract][Full Text] [Related]
11. Validation of the 12-gene colon cancer recurrence score in NSABP C-07 as a predictor of recurrence in patients with stage II and III colon cancer treated with fluorouracil and leucovorin (FU/LV) and FU/LV plus oxaliplatin.
Yothers G; O'Connell MJ; Lee M; Lopatin M; Clark-Langone KM; Millward C; Paik S; Sharif S; Shak S; Wolmark N
J Clin Oncol; 2013 Dec; 31(36):4512-9. PubMed ID: 24220557
[TBL] [Abstract][Full Text] [Related]
12. Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses.
Yothers G; O'Connell MJ; Allegra CJ; Kuebler JP; Colangelo LH; Petrelli NJ; Wolmark N
J Clin Oncol; 2011 Oct; 29(28):3768-74. PubMed ID: 21859995
[TBL] [Abstract][Full Text] [Related]
13. Oral tegafur-uracil plus folinic acid versus intravenous 5-fluorouracil plus folinic acid as adjuvant chemotherapy of colon cancer.
Kim DJ; Kim TI; Suh JH; Cho YS; Shin SK; Kang JK; Kim NK; Kim WH
Yonsei Med J; 2003 Aug; 44(4):665-75. PubMed ID: 12950123
[TBL] [Abstract][Full Text] [Related]
14. Edrecolomab alone or in combination with fluorouracil and folinic acid in the adjuvant treatment of stage III colon cancer: a randomised study.
Punt CJ; Nagy A; Douillard JY; Figer A; Skovsgaard T; Monson J; Barone C; Fountzilas G; Riess H; Moylan E; Jones D; Dethling J; Colman J; Coward L; MacGregor S
Lancet; 2002 Aug; 360(9334):671-7. PubMed ID: 12241873
[TBL] [Abstract][Full Text] [Related]
15. The addition of low-dose leucovorin to the combination of 5-fluorouracil- levamisole does not improve survival in the adjuvant treatment of Dukes' C colon cancer. IKN Colon Trial Group.
Bleeker WA; Mulder NH; Hermans J; Otter R; Plukker JT
Ann Oncol; 2000 May; 11(5):547-52. PubMed ID: 10907947
[TBL] [Abstract][Full Text] [Related]
16. Real-world tolerance and outcomes of oxaliplatin-based adjuvant chemotherapy for stage III colon cancer-Does dose intensity matter?
Yoon R; Wilkinson K; Gabriel G; Kadaan N; Roberts T; Lim S; Asghari R; Lee CS; Chua W; Ng W
Asia Pac J Clin Oncol; 2024 Feb; 20(1):63-70. PubMed ID: 37211922
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant therapy of colon cancer.
Macdonald JS; Astrow AB
Semin Oncol; 2001 Feb; 28(1):30-40. PubMed ID: 11254865
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant chemotherapy in stage III colon cancer with 5-fluorouracil and levamisole versus 5-fluorouracil and leucovorin.
Dencausse Y; Hartung G; Sturm J; Kopp-Schneider A; Hagmüller E; Wojatschek C; Lindemann H; Fritze D; Queisser W
Onkologie; 2002 Oct; 25(5):426-30. PubMed ID: 12415196
[TBL] [Abstract][Full Text] [Related]
19. Machine Learning Predicts Oxaliplatin Benefit in Early Colon Cancer.
Chen L; Wang Y; Cai C; Ding Y; Kim RS; Lipchik C; Gavin PG; Yothers G; Allegra CJ; Petrelli NJ; Suga JM; Hopkins JO; Saito NG; Evans T; Jujjavarapu S; Wolmark N; Lucas PC; Paik S; Sun M; Pogue-Geile KL; Lu X
J Clin Oncol; 2024 May; 42(13):1520-1530. PubMed ID: 38315963
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of adjuvant FOLFOX and 5FU/LV chemotherapy for patients with stage II colon cancer.
Ayvaci MU; Shi J; Alagoz O; Lubner SJ
Med Decis Making; 2013 May; 33(4):521-32. PubMed ID: 23313932
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
